Immunobiologicals in dermatology

Silva, Dimitri Luz Felipe da; Secamilli, Elisa Nunes; Beleli, Mariana Valbon; Massuda, Juliana Yumi; Franca, Andrea F.E.C.; Magalhães, Renata F.

doi:10.1016/j.abd.2021.05.016

Acessibilidade / Reportar erro

Brasil

Anais Brasileiros de Dermatologia

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Continuing Medical Education • An. Bras. Dermatol. 97 (3) • May-Jun 2022 • https://doi.org/10.1016/j.abd.2021.05.016 copy

Immunobiologicals in dermatology^☆ ☆ Study conducted at the Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

Immunobiologicals are a reality in current clinical practice and have increasingly gained space in the inflammatory disease scenario, especially in dermatology, with approved drugs for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to many others undergoing study. It is important for dermatologists to have knowledge of the medications approved in Brazil, for the best management of dermatoses, in addition to the fact that they represent hope for improvement in patients with chronic diseases.

Keywords
Arthritis, psoriatic; Dermatitis, atopic; Hidradenitis suppurativa; Psoriasis

Medication	Action mechanism	Half-life	Indication (package insert)	Presentation	Dosage
Etanercept	Anti-TNF-α	3 days	PSO (adults and children ≥8 years), RA, PA, AS and axial AS	Pre-filled syringe, 25 and 50 mg	I: 50 mg SC, 2× week for 12 weeks;
Etanercept	Anti-TNF-α	3 days	PSO (adults and children ≥8 years), RA, PA, AS and axial AS	Pre-filled syringe, 25 and 50 mg	M: 50 mg SC, 1× week ^a a Etanercept pediatric dose- 0,8 mg/kg (max. 50 mg) SC, 1× week.
Infliximab	Anti-TNF-α	25 days	PSO, PA, RA, AS (adults); CD and RU (adults and ≥ 6 years)	Ampoule vial with lyophilized powder 100 mg	I: 5 mg/kg IV, weeks 0-2-6
Infliximab	Anti-TNF-α	25 days	PSO, PA, RA, AS (adults); CD and RU (adults and ≥ 6 years)	Ampoule vial with lyophilized powder 100 mg	M: 5 mg/kg IV 8/8 weeks
Adalimumab	Anti-TNF-α	14 days	PSO, PA, HS, RU, RA, AS, axial AS (adults); CD, Uveitis, JIA and ERA (adults and children ≥ 2 years)	Syringe, ampoule vial and pen, 20, 40 and 80 mg	I: 80 mg D0, 40 mg D7,
Adalimumab	Anti-TNF-α	14 days		Syringe, ampoule vial and pen, 20, 40 and 80 mg	M: 40 mg every 14 days ^b b Adalimumab par HS - I: 160 mg D0, 80 mg D14, 40 mg D28; M: 40 mg every 7 days.
Certolizumab-pegol	Anti-TNF-α	14 days	PA, CD, RA and AS	Pre-filled syringe, 200 mg	I: 400 mg SC, weeks 0-2-4;
Certolizumab-pegol	Anti-TNF-α	14 days	PA, CD, RA and AS	Pre-filled syringe, 200 mg	M: 200 mg SC, every 2 weeks or 400 mg SC, every 4 weeks ^c c Dose corresponding to psoriatic arthritis.
Ustekinumab	Anti-IL-12,23	10 weeks	PSO, PA, CD	Syringe and ampoule vial, 45 and 90 mg	I: 45 mg SC weeks 0-4;
Ustekinumab	Anti-IL-12,23	10 weeks	PSO, PA, CD	Syringe and ampoule vial, 45 and 90 mg	M: 45 mg SC every 12 weeks ^d d In patients weighing more than 100 kg, the dose should be 90 mg; Pediatric used from 9 years of age on.
Secukinumab	Anti-IL-17	27 days	PSO, PA and AS	Pre-filled pen, 150 mg	I: 300 mg SC weeks 0-1-2-3-4;
Secukinumab	Anti-IL-17	27 days	PSO, PA and AS	Pre-filled pen, 150 mg	M: 300 mg SC every 4 weeks
Ixekizumab	Anti-IL-17	13 days	PSO	Pre-filled pen, 80 mg	I: 160 mg SC weeks 0, 80 mg weeks 2-4-6-8-10-12;
Ixekizumab	Anti-IL-17	13 days	PSO	Pre-filled pen, 80 mg	M: 80 mg SC every 4 weeks
Guselkumab	Anti-IL-23	17 days	PSO; PA	Pre-filled syringe, 100 mg	I: 100 mg SC weeks 0-4;
Guselkumab	Anti-IL-23	17 days	PSO; PA	Pre-filled syringe, 100 mg	M: 100 mg SC every 8 weeks
Risankizumab	Anti-IL-23	4 weeks	PSO	Pre-filled syringe, 75 mg	I: 150 mg SC weeks 0-4;
Risankizumab	Anti-IL-23	4 weeks	PSO	Pre-filled syringe, 75 mg	M: 150 mg SC every 12 weeks

Medication	Action mechanism	Half-life	Indication (package insert)	Presentation	Dosage
Omalizumab	Anti-IgE	26 days	CSU, allergic asthma	Ampoule-vial with lyophilized powder 100 mg	300 mg SC every 4 weeks
Dupilumab	Anti-IL-4, IL-13	7 days	Moderate to severe AD	Pre-filled syringe, 300 mg	I: 600 mg SC, without 0
Dupilumab	Anti-IL-4, IL-13	7 days	Moderate to severe AD	Pre-filled syringe, 300 mg	M: 300 mg SC, every 2 weeks
Rituximab	Anti- B Lymphocytes	3 weeks	Moderate to severe PV, RA, Leukemia, Lymphomas, Vasculitis	Ampoule-vial with lyophilized powder 100 mg/10 mL or 500 mg/50 m L	2 doses of 1000 mg with a 14-day interval^a a Dose recommended for RA.

Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] ∗Corresponding author. E-mail:dimitriluz@hotmail.com (D.L. Silva).

Brasil

Brasil

Immunobiologicals in dermatology☆ ☆ Study conducted at the Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.

Abstract

Immunobiologicals in dermatology^☆ ☆ Study conducted at the Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.